GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » Shiller PE Ratio

Processa Pharmaceuticals (Processa Pharmaceuticals) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Processa Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Processa Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Processa Pharmaceuticals Shiller PE Ratio Chart

Processa Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Processa Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Processa Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Processa Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Processa Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Shiller PE Ratio falls into.



Processa Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Processa Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Processa Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.11/131.7762*131.7762
=-1.110

Current CPI (Mar. 2024) = 131.7762.

Processa Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -107.800 100.560 -141.264
201409 -98.000 100.428 -128.591
201412 -303.801 99.070 -404.097
201503 -58.800 99.621 -77.779
201506 -186.200 100.684 -243.701
201509 -29.400 100.392 -38.591
201512 -39.200 99.792 -51.764
201603 -9.800 100.470 -12.854
201606 -9.800 101.688 -12.700
201609 -9.800 101.861 -12.678
201612 0.000 101.863 0.000
201703 -9.800 102.862 -12.555
201706 -4.764 103.349 -6.074
201709 -19.600 104.136 -24.802
201712 -6.086 104.011 -7.711
201803 -4.200 105.290 -5.257
201806 -4.200 106.317 -5.206
201809 -2.800 106.507 -3.464
201812 -1.600 105.998 -1.989
201903 -2.800 107.251 -3.440
201906 -3.600 108.070 -4.390
201909 -3.200 108.329 -3.893
201912 -4.600 108.420 -5.591
202003 -3.200 108.902 -3.872
202006 -2.600 108.767 -3.150
202009 -11.000 109.815 -13.200
202012 -20.244 109.897 -24.274
202103 -2.800 111.754 -3.302
202106 -4.000 114.631 -4.598
202109 -3.800 115.734 -4.327
202112 -4.200 117.630 -4.705
202203 -4.000 121.301 -4.345
202206 -6.400 125.017 -6.746
202209 -7.400 125.227 -7.787
202212 -16.050 125.222 -16.890
202303 -3.530 127.348 -3.653
202306 -2.000 128.729 -2.047
202309 -1.600 129.860 -1.624
202312 -1.680 129.419 -1.711
202403 -1.110 131.776 -1.110

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Processa Pharmaceuticals  (NAS:PCSA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Processa Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Processa Pharmaceuticals (Processa Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.
Executives
Wendy Guy officer: Chief Administrative Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker officer: Chief Financial Officer 9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Patrick Lin officer: Chief Business - Strategy Off 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
George K Ng officer: Chief Executive Officer C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson director 319 SOUTH NARDO, SOIANA BEACH CA 92075
Justin W Yorke director C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
Geraldine Pannu director 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
David Young director, 10 percent owner, officer: President & CEO 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Robert Michael Floyd officer: Chief Operating Officer C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora officer: Chief Development Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076

Processa Pharmaceuticals (Processa Pharmaceuticals) Headlines

From GuruFocus

PCS12852 Improves Gastric Emptying in Gastroparesis Patients

By Value_Insider Value_Insider 11-08-2022